Royal Bank of Canada Has $62.87 Million Stock Holdings in Insulet Corporation $PODD

Royal Bank of Canada reduced its position in shares of Insulet Corporation (NASDAQ:PODD) by 16.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 299,625 shares of the medical instruments supplier’s stock after selling 60,889 shares during the period. Royal Bank of Canada’s holdings in Insulet were worth $62,872,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC raised its holdings in Insulet by 114.6% in the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet during the 4th quarter worth approximately $26,000. DV Equities LLC bought a new stake in Insulet during the 4th quarter worth approximately $28,000. Elyxium Wealth LLC acquired a new position in Insulet in the 4th quarter valued at approximately $28,000. Finally, Mcguire Capital Advisors Inc. acquired a new position in Insulet in the 4th quarter valued at approximately $29,000.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on PODD shares. Oppenheimer dropped their price target on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Royal Bank Of Canada decreased their price objective on Insulet from $280.00 to $245.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Wells Fargo & Company lowered their target price on Insulet from $360.00 to $255.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Raymond James Financial set a $216.00 target price on Insulet in a research report on Monday, June 8th. Finally, JPMorgan Chase & Co. cut their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $233.38.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: UBS Group began research coverage of Insulet, potentially increasing institutional visibility and investor attention. However, the available report does not disclose UBS’s rating or price target. Insulet research coverage started at UBS Group
• Neutral Sentiment: The legal notices concern alleged violations of federal securities laws by Insulet and certain executives. The allegations have not been proven, and the financial impact of the litigation remains uncertain. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: Several firms, including Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Bleichmar Fonti & Auld, Schall Brown & Schwartz, DJS Law Group, Rosen Law Firm, and Glancy Prongay, publicized the pending class action. The notices generally cover investors who purchased Insulet securities between February 21 or May 21, 2025, and May 26, 2026, and allege investor losses related to disclosures involving defective Omnipod manufacturing controls. Bleichmar Fonti & Auld securities lawsuit notice
• Negative Sentiment: The concentration of similar legal announcements may amplify concerns about potential damages, management accountability, regulatory scrutiny, and reputational risk, even though no judgment or settlement has been reported. Insulet investor alert from Schall Brown & Schwartz

Insulet Stock Down 0.2%

Insulet stock opened at $165.35 on Friday. The firm has a market cap of $11.45 billion, a price-to-earnings ratio of 38.45, a PEG ratio of 1.15 and a beta of 1.11. Insulet Corporation has a 52-week low of $138.79 and a 52-week high of $354.88. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The firm has a 50 day moving average price of $155.26 and a two-hundred day moving average price of $198.24.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s quarterly revenue was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts predict that Insulet Corporation will post 6.45 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.36% of the company’s stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.